Neurology

Patients with MASH and stage II or III fibrosis treated with ervogastat and clesacostat are more likely than those on placebo to achieve MASH resoluti...

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments...

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activi...

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detectin...

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and rice may offer some prot...

Panelists discuss how approximately 20% to 30% of patients compliant with CPAP therapy still experience pathological sleepiness, requiring clinicians...

Panelists discuss how FDA-approved medications like modafinil, armodafinil, and solriamfetol serve both therapeutic and diagnostic purposes in treatin...

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer, urging further research for validation.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University detailed published findings on GLP-1 receptor agonists signif...